← brief for 2026-09-03 · Slowing decline

Ketoacidosis with SGLT2 inhibitors in routine clinical practice of type 2 diabetes: Scandinavian cohort and nested case-control study.

Key takeaways

SGLT2 inhibitors, the drug family that includes dapagliflozin and empagliflozin, can cause ketoacidosis, a dangerous buildup of acid in the blood. This study used national health records from Sweden, Denmark and Norway to count how often that happens in everyday care, who is at higher risk, and how those patients fare. Because it tracks people as they were already treated rather than assigning treatment at random, it shows a link and cannot prove the drug caused each case. It still matters for anyone with kidney disease taking one of these drugs, since real-world numbers have been thin.

Who did this work

Kadesjö E · Söderling J · Hviid A · Wintzell V · Svanström H · Eliasson B · Gudbjörnsdóttir S · Melbye M · Hveem K · Jonasson C · Andersson DP · Pasternak B

Source

Article · PubMed, the drug frontier · 2026 Sep 1
https://pubmed.ncbi.nlm.nih.gov/42679839/